Aug 05, 2025 • Zacks Commentary
BULLISH
Earnings Estimates Moving Higher for Amicus Therapeutics ( FOLD ) : Time to Buy?
Amicus Therapeutics (FOLD) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Aug 05, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
Does Amicus Therapeutics ( FOLD ) Have the Potential to Rally 138.21% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 138.2% in Amicus Therapeutics (FOLD). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Aug 01, 2025 • Motley Fool
SOMEWHAT-BULLISH
Amicus ( FOLD ) Q2 Revenue Jumps 22%
Amicus Therapeutics ( NASDAQ:FOLD ) , a specialist in rare disease medicines, delivered quarterly results on July 31, 2025 that notably surpassed expectations on both GAAP revenue and non-GAAP earnings. The company reported GAAP revenue of $154.7 million, up from $126.7 million ( GAAP ) a year ...
Aug 01, 2025 • Zacks Commentary
SOMEWHAT-BULLISH
FOLD Q2 Earnings Miss Mark, Revenues Beat on Higher Product Sales
Amicus misses second-quarter earnings estimates but beats the same for revenues, driven by strong sales of Galafold and Pombiliti + Opfolda.
Jul 31, 2025 • Zacks Commentary
NEUTRAL
Amicus Therapeutics ( FOLD ) Misses Q2 Earnings Estimates
Amicus Therapeutics (FOLD) delivered earnings and revenue surprises of -50.00% and +4.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?